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Abstract
The adjuvanticity of bacterial adenylate cyclase toxins has been ascribed to their capacity, largely mediated by cAMP, to
modulate APC activation, resulting in the expression of Th2–driving cytokines. On the other hand, cAMP has been
demonstrated to induce a Th2 bias when present during T cell priming, suggesting that bacterial cAMP elevating toxins may
directly affect the Th1/Th2 balance. Here we have investigated the effects on human CD4+ T cell differentiation of two
adenylate cyclase toxins, Bacillus anthracis edema toxin (ET) and Bordetella pertussis CyaA, which differ in structure, mode of
cell entry, and subcellular localization. We show that low concentrations of ET and CyaA, but not of their genetically
detoxified adenylate cyclase defective counterparts, potently promote Th2 cell differentiation by inducing expression of the
master Th2 transcription factors, c-maf and GATA-3. We also present evidence that the Th2–polarizing concentrations of ET
and CyaA selectively inhibit TCR–dependent activation of Akt1, which is required for Th1 cell differentiation, while
enhancing the activation of two TCR–signaling mediators, Vav1 and p38, implicated in Th2 cell differentiation. This is at
variance from the immunosuppressive toxin concentrations, which interfere with the earliest step in TCR signaling,
activation of the tyrosine kinase Lck, resulting in impaired CD3f phosphorylation and inhibition of TCR coupling to ZAP-70
and Erk activation. These results demonstrate that, notwithstanding their differences in their intracellular localization, which
result in focalized cAMP production, both toxins directly affect the Th1/Th2 balance by interfering with the same steps in
TCR signaling, and suggest that their adjuvanticity is likely to result from their combined effects on APC and CD4+ T cells.
Furthermore, our results strongly support the key role of cAMP in the adjuvanticity of these toxins.
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Introduction
Development of an effective humoral immune response is
crucially dependent on T cell help. The last step of B cell
differentiation, involving immunoglobulin affinity maturation and
isotype switching, occurs in peripheral lymphoid organs under the
guidance of a specialized CD4+ T cell subset, known as T helper 2
(Th2). These cells provide both soluble (IL-4) and membrane-
bound (CD40L) factors essential for terminal differentiation of
antigen specific B cells [1]. Th2 cells are characterized by
expression of a unique complement of cytokines, including IL-4,
IL-5, IL-10 and IL-13, which are expressed through a complex
transcriptional program involving chromatin remodelling at the
Th2 cytokine locus control region and de novo expression of the
lineage specific transcription factors c-maf and GATA-3 [2].
Priming the Th2 differentiation program in naive CD4+ T cells
requires essential cues which are provided by antigen presenting
cells (APC) in the form of cytokines. Engagement of the T cell
antigen receptor (TCR) on naive T cells in the presence of IL-4
promotes their differentiation to Th2 effector cells, whilst
simultaneously antagonising committment to the alternative Th1
lineage, which controls cell mediated immunity [1,2]. Additional
factors present during T cell priming may profoundly affect the
developmental program of helper T cells. Among these, of
paramount importance is the second messenger cAMP, which is
produced by cellular adenylate cyclases in response to heterotri-
meric G-protein coupled surface receptors, such as the receptors
for prostaglandin E2, a proinflammatory prostanoid produced by
activated APC [3]. cAMP has been shown to favour Th2 cell
differentiation and GATA-3 dependent production of IL-4 and
IL-5 through a pathway regulated by phosphoinositide-dependent
kinase 1 (PDK1) and protein kinase A (PKA) [4–9].
Suppression of both innate and adaptive immune responses
through elevation of intracellular cAMP to supraphysiological
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levels represents a powerful strategy of immune evasion by many
bacterial pathogens. This can be achieved indirectly, as for the
bacterial enterotoxins, cholera toxin (CT) and E. coli heat-labile
enterotoxin (LT), which enhance intracellular cAMP production
by activating the Gsa subunit of heterotrimeric G-proteins coupled
to cellular adenylate cyclases [10]. Alternatively, bacteria such as
B. anthracis or B. pertussis produce and deliver into target cells an
adenylate cyclase toxin, the edema factor (EF) and CyaA
respectively, respectively, which are themselves adenylate cyclases
that catalyze the production of large amounts of cAMP [11,12].
Notwithstanding their immmunosuppressive activity, when ad-
ministered to mice at subtoxic concentrations together with
antigen these toxins potentiate antibody responses, an effect
associated with enhanced generation of antigen specific Th2 cells
[13–17]. The adjuvanticity of cAMP elevating toxins is believed to
result from their capacity to modulate APC differentiation and
function. This is exemplified by ET and CyaA, which have been
reported to selectively inhibit the production by macrophages and
dendritic cells of the master Th1 polarizing cytokine, IL-12, while
upregulating IL-4 and IL-10 production, thereby enhancing the
induction of Th2 cells [13–15,17–19]. The finding that both non-
hydrolysable cAMP analogues and PGE2 evoke similar effects on
APC [18–21] strongly supports the notion that the cAMP
elevating activity of these toxins largely accounts for their capacity
to differentially affect cytokine production by APC.
We and others have demonstrated that ET and CyaA potently
suppress T cell activation [22–24]. This activity results from their
capacity to uncouple TCR engagement from activation of the
MAP kinase cascade, which is essential for the initiation of the
transcriptional program governing T cell activation, proliferation
and subsequent differentiation to armed effector cells. Here we
have investigated the additional possibility, suggested by the
instructive role of the cAMP/PKA axis in Th2 cell differentiation
[4–9], that these bacterial toxins might alter TCR signaling to
promote naive T cell committment to the Th2 lineage when used
at low concentrations. The results show that both ET and CyaA,
but not their enzymatically deficient counterparts, directly affect
the Th1/Th2 balance by selectively inhibiting TCR dependent
activation of the Th1 driving kinase Akt1 while enhancing
activation of two essential components of the TCR signaling
cascade selectively implicated in human Th2 cell differentiation,
the guanine nucleotide exchanger Vav1 and the stress kinase p38.
These data support the notion that the adjuvanticity of these
cAMP elevating toxins results from their combined effects on APC
and CD4+ T cells.
Results
Low concentrations of ET and CyaA catalyze sustained
production of cAMP and induce PKA activation in T cells
Both B. anthracis ET and B. pertussis CyaA potently suppress T
cell activation through their cAMP elevating activity [22–24]. To
assess the potential effect of these toxins on CD4+ T cell
differentiation, a permissive concentration of ET or CyaA was
identified in a T cell proliferation assay. Genetically inactivated
mutants of ET and CyaA, EL1 [25] and CyaA-E5 [26]
respectively, were included as controls. Both ET and CyaA
inhibited T cell proliferation in a concentration-dependent
manner (Figure 1A). Conversely, neither EL1 or CyaA-E5 affected
T cell proliferation (Figure 1B). The toxin concentration selected
for the polarization experiments, 0.11 nM and 0.28 nM for ET
and CyaA respectively, resulted in ,40% inhibition in the
proliferation assays (see arrow in Figure 1A).
A time course analysis of intracellular cAMP production in
purified peripheral blood T cells showed that these concentrations
of ET and CyaA induced a detectable accumulation of
intracellular cAMP, albeit at much lower levels as compared to
that obtained with high toxin concentrations (Figure 2A, top). The
kinetics of cAMP production by ET and CyaA were significantly
different. A fully immunosuppressive ET concentration resulted in
a slow increase in intracellular cAMP beginning from 2 h, with a
further progressive rise up to 8 h (Figure 2A, top left). On the
other hand, a fully immunosuppressive concentration of CyaA
evoked a rapid rise of cAMP to plateau levels beginning from the
earliest time point analyzed, and the levels of cAMP remained
high up to 8 h (Figure 2A, top left). High cAMP concentrations
were still measurable after 24 h (data not shown). The kinetics of
cAMP production by immunosuppressive concentrations of ET
and CyaA were largely reproduced by the low toxin concentra-
tions selected for the studies on T cell polarization (Figure 2A, top
right, and data not shown for 24 h). No increase in cAMP was
elicited by EL1 and CyaA-E5, even at the highest concentration
used (Figure 2A, bottom left).
To understand whether the modest increase in the levels of
cAMP catalyzed by low concentrations of ET or CyaA was
sufficient to elicit a biological response, we measured the activity of
PKA, one of the major cellular targets of cAMP. As a readout of
PKA activation we used an antibody specific for the phosphor-
ylated PKA consensus, R-X-X-pT-X-X/R-R-X-pS-X-X, which
recognizes phosphorylated PKA substrates. The increase in
intracellular cAMP following T cell treatment with high
concentrations of ET or CyaA resulted in a strong potentiation
of PKA activity, as shown by the qualitative and quantitative
changes in the phosphoprotein pattern in lysates from toxin-
treated cells compared to untreated cells (Figure 2B, top panel). A
similar enhancement in PKA activity was also observed in cells
treated with low concentrations of ET or CyaA, despite the smaller
increase in intracellular cAMP measured under these conditions
(Figure 2B, top panel). Interestingly, notwithstanding the different
interacellular localization of the two adenylate cyclase toxins, there
Author Summary
Colonization by pathogens requires keeping at bay the
host immune defenses, at least at the onset of infection.
The adenylate cyclase (AC) toxins produced by many
pathogenic bacteria assist in this crucial function by
catalyzing the production of cAMP, which acts as a potent
immunosuppressant. Nevertheless, at low concentrations,
these toxins act as adjuvants, enhancing antibody
responses to vaccination. We have investigated the
molecular basis of the immunomodulatory activities of
two AC toxins, Bacillus anthracis edema toxin and
Bordetella pertussis CyaA. We show that high toxin
concentrations inhibit activation of T lymphocytes, which
orchestrate the adaptive immune response against path-
ogens, whereas low toxin concentrations promote differ-
entiation of helper T lymphocytes to Th2 effectors, which
are required for development of antibody-producing cells.
Both the immunosuppressant and Th2–driving activities of
the toxins are dependent on cAMP. The results demon-
strate that, dependent on their concentration, the AC
toxins of B. anthracis and B. pertussis evoke distinct
responses on target T lymphocytes by differentially
modulating antigen receptor signaling, resulting either in
suppression of T cell activation or Th2 cell differentiation.
These results are of relevance to the evolution of disease in
infected individuals and provide novel mechanistic insight
into the adjuvanticity of these toxins.
Shaping of TCR Signaling by AC Toxins
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was a general overlap in the phosphoprotein pattern observed in
cells treated with ET or CyaA. Consistent with the agonistic
activity of ET and CyaA on PKA, analysis of the phosphorylation
state of the transcriptional activator CREB, a specific PKA
substrate, showed that low toxin concentrations induced CREB
phosphorylation, albeit to a lesser extent compared to high toxin
concentrations (Figure 2B, middle panel). The agonistic effect of
the toxins was abrogated to a significant extent when cells were
pretreated with pharmacological PKA inhibitors (H89 or KT5720)
(Figure 2C and data not shown). Moroever, no CREB phosphor-
ylation was observed in T cells treated with the adenylate cyclase
defective ET or CyaA mutant (Figure 2C), supporting the notion
that the effects of the toxins are mediated by the cAMP/PKA axis.
Of note, maximal activation of both PKA and CREB was
observed in cells stimulated by TCR/CD3 cross-linking
(Figure 2B), consistent with the potent agonistic activity of the
receptor on cAMP production (Figure 2A, bottom right).
However, as opposed to the long-lasting increase in cAMP elicited
by the toxins, TCR engagement resulted in a transient increase in
intracellular cAMP (Figure 2A, bottom right). No further
significant enhancement in TCR-dependent PKA or CREB
activation was observed in T cells treated with ET or CyaA
(Figure 2B and respective legend), despite the increase in cAMP
production observed under these conditions (Figure 2D), indicat-
ing that PKA and CREB activation reaches plateau levels in
response to the cAMP burst elicited by the TCR.
ET and CyaA promote Th2 cell differentiation
To assess the impact of low concentrations of ET and CyaA on
human helper T cell polarization, enriched human CD4+ T cells
from healthy donors were exposed to ET or CyaA and
subsequently primed by TCR/CD3 cross-linking using immobi-
lized anti-CD3 mAb. After 10 days, cells were washed, and
restimulated for 24 h or 48 h using the same anti-CD3 mAb. The
identity of the Th subset into which cells had differentiated was
determined by ELISPOT analysis of cytokine production. As
shown in Figure 3A, priming of cells that had been exposed to low
concentrations of ET or CyaA resulted in a dramatic increase in
production of the Th2 cytokines, IL-4 and IL-13, to levels close to
those measured in cells primed to differentiate to the Th2 subset
(TCR/CD3 cross-linking in the presence of IL-4). Conversely,
consistent with the mutual antagonism of the Th1/Th2 differen-
tiation programs, ET or CyaA had a modest inhibitory effect on
production of the Th1 cytokines IFNc and TNF-a (Figure 3B). No
significant enhancement in Th2 cytokines above the levels
produced by T cells primed in neutral conditions (TCR/CD3
cross-linking alone) was observed when cells were pretreated with
the adenylate cyclase defective EL1 or CyaA-E5 mutants
(Figure 3A), indicating that the Th2 driving activity of ET and
CyaA is dependent on their capacity to produce cAMP.
Differentiation of helper T cells to the Th2 subset is crucially
dependent on expression of the lineage specific transcription
factors c-maf and GATA-3, which are essential for transcriptional
regulation of the Th2 cytokine control locus [2]. To understand
whether ET and CyaA promote production of IL-4 and IL-13 by
shaping the transcriptional program triggered by the TCR in
naive T cells, resulting in expression of lineage specific
transcription factors, the levels of c-maf and GATA-3 mRNA in
T cells primed in the presence of either toxin were measured by
real-time RT-PCR. Both ET and CyaA potently upregulated
expression of c-maf and GATA-3 to levels comparable or higher
than those detectable in T cells primed in the presence of IL-4
(Figure 4A). Conversely, expression of the Th1 lineage specific
Figure 1. Concentration dependent suppression of T cell
proliferation by CyaA and ET. (A) [3H]-thymidine uptake by PBL
stimulated for 48 h by CD3 cross-linking in the presence or absence of
the indicated concentrations of CyaA (top) or ET (bottom). The results,
obtained on triplicate samples of PBL from 5 independent donors, are
expressed as % [3H]-thymidine uptake (cpm) by CyaA or ET treated cells
compared to control cells stimulated in the absence of either toxin
(taken as 100%). The arrow shows the toxin concentration selected for
the polarization experiments (CyaA, 0.28 nM; ET, 0.11 nM). (B) [3H]-
thymidine uptake by PBL stimulated for 48 h by CD3 cross-linking in the
presence or absence of either CyaA and ET or the respective adenylase
deficient mutants (45 nM CyaA/CyaA-E5, 110 nM ET/EL1). The results
are expressed as in A. ***P#0.001; **P#0.01; *P#0.05. Error bars, SD.
doi:10.1371/journal.ppat.1000325.g001
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Figure 2. cAMP production and PKA activation in T cells treated with high and low concentrations of CyaA and ET. (A) Time course
analysis of cAMP production in purified peripheral blood T lymphocytes treatedwith high (CyaA hi, 45 nM ; ET hi, 110 nM) (top left) or low (CyaA lo, 0.28 nM;
ET lo, 0.11 nM) (top right) concentrations of CyaA or ET, or activated by TCR/CD3 cross-linking (bottom right). The histogram on the bottom left panel also
includes the quantification of cAMP in lysates of T cells treated with the adenylase cyclase deficient CyaA and ET mutants (45 nM CyaA-E5, 110 nM EL1) for
2 h or 6 h, respectively. The results, which show the levels of cAMPmeasured in T cell lysates, are expressed as fmoles/106 cells. Representative experiments,
each carried out on duplicate samples from individual healthy donors, are shown (n$4). (B) Top, Immunoblot analysis of the phosphorylation state of PKA
substrates in post-nuclear supernatants of T cells treated with 45 nM CyaA (CyaA hi) or 0.28 nM CyaA (CyaA lo), or 110 nM ET (ET hi) or 0.11 nM ET (ET lo),
for 2 h (CyaA) or 6 h (ET), and then lysed as such or after stimulation for 1 min with anti-CD3mAb (CD3). A sample stimulated with anti-CD3mAb alonewas
also included. The immunoblot was carried out using an antibody which recognizes a phosphorylated PKA consensus sequence (see Materials and
Methods). The stripped filter was reprobed with a phosphospecific antibody which recognizes the active form of CREB (middle). The fold activation of CREB
in CyaA/ET treated samples vs untreated control in the experiment shown was the following: CyaA low, 8.3; CyaA high, 19.0; ET low, 8.7; ET high, 79.9. The
levels of phospho-CREB in the samples treated with CyaA or ET in combination with anti-CD3 mAb vs samples treated with anti-CD3 mAb alone (taken as
100%) were the following: CyaA low+CD3, 98.164.8%; CyaA high+CD3, 103.468.7%; ET low+CD3, 102.163.2%; ET high+CD3, 112.168.1% (n=3). A control
anti-actin blot is shown below. None of the treatments modified the expression levels of CREB (data not shown). Representative experiments are presented
(n$3). Themigration of molecular mass markers is indicated. (C) Quantification of CREB phosphorylation in post-nuclear supernatants of T cells treated with
45 nM CyaA (CyaA hi)/CyaA-E5 or 0.28 nM CyaA (CyaA lo), or 110 nM ET (ET hi) /EL1 or 0.11 nM ET (ET lo), for 2 h (CyaA) or 6 h (ET). Where indicated, cells
were pretreated for 1 h with 20 mM H89. A sample stimulated for 30 min with 100 mM 8-CPT was included as positive control. The data were obtained by
laser densitometry of anti-phospho-CREB immunoblots. The results are expressed as relative CREB phosphorylation (fold activation vs untreated controls)
(n=2). (D) Quantification of cAMP in lysates of T cells treated as in B. The results, which show the levels of cAMPmeasured in T cell lysates, are expressed as
fmoles/106 cells. A representative experiment, carried out on duplicate samples from an individual healthy donor, is shown (n=3). ***P#0.001; **P#0.01;
*P#0.05. Error bars, SD.
doi:10.1371/journal.ppat.1000325.g002
Shaping of TCR Signaling by AC Toxins
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Figure 3. CyaA and ET promote Th2 cell differentiation through their cAMP elevating activity. Enriched CD4+ T cells from 6 healthy
donors were primed with anti-CD3 mAb, as such or following pretreatment for 2 h with 0.28 nM CyaA/CyaA-E5, or with 0.11 nM ET/EL1. Cells primed
in Th2- (IL-4) or Th1- (IL-12) inducing conditions were included as controls. After 10 days cells were washed and restimulated with anti-CD3 mAb for
48 and 24 h respectively, and the levels of IL-4 and IL-13 (A) and IFN-c and TNF-a (B) were quantified by ELISPOT. The results, obtained on duplicate
samples, are expressed as % spot-forming units by CyaA or ET treated cells compared to control cells primed in the absence of either toxin (taken as
100%). ***P#0.0001; **P#0.001; *P#0.01. Error bars, SD.
doi:10.1371/journal.ppat.1000325.g003
Shaping of TCR Signaling by AC Toxins
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transcription factor T-bet was not significantly affected in T cells
primed in the presence of either CyaA or ET (Figure 4B).
Low concentrations of ET and CyaA selectively impair
TCR–dependent activation of Akt1, while potentiating
activation of Vav1 and p38
TCR signaling is initiated by Lck, a T cell specific Src family
protein tyrosine kinase which is responsible for phosphorylation of
the ITAMs within the f chain of the CD3 complex. As all Src
kinases, Lck is negatively regulated by a C-terminal tyrosine
residue, Y505, which, when phosphorylated, establishes an
intramolecular interaction with the SH2 domain, resulting in a
close, inactive conformation. The inhibitory tyrosine residue is
phosphorylated by Csk, which in resting cells is maintained close
to Lck in lipid rafts through interaction with the PAG adaptor and
whose activity is potentiated by PKA dependent phosphorylation
of a serine residue at position 364 [27]. By elevating intracellular
cAMP, ET and CyaA have therefore the potential to antagonize
TCR signaling beginning from the earliest step. Analysis of the
phosphorylation state of Y505 on Lck using a phosphospecific
antibody revealed that high concentrations of ET or CyaA
effectively block TCR dependent dephosphorylation of Lck
(Figure 5A and 5B). This activity was not reproduced by the
respective adenylate cyclase defective mutants (Figure 5B), sup-
porting the notion that the suppressive effect of ET and CyaA on
TCR dependent Lck activation is mediated by cAMP. No
enhancement in Lck kinase activity in response to TCR
engagement was moreover observed when cells were pretreated
with high concentrations of ET or CyaA, as assessed by measuring
Lck autophosphorylation in in vitro kinase assays (data not shown).
Consistent with the failure of the TCR to trigger activation of Lck
in the presence of either toxin, both TCR dependent CD3f
phosphorylation and activation of the effector kinase ZAP-70,
which occurs following recruitment to the phosphorylated ITAMs
of CD3f, were found to be inhibited by ET or CyaA (Figure 5A
and 5B). In agreement with previous reports [22–24], activation of
the MAP kinase cascade, which couples these early signaling
events to gene transcription, was found to be impaired by
immunosuppressive concentrations of ET or CyaA, as assessed
using as a readout phosphorylation of Erk1/2 (Figure 5A and 5B).
Conversely, neither CD3f and ZAP-70 phosphorylation, nor
Erk1/2 phosphorylation, were affected when the TCR was
stimulated in cells exposed to low, Th2 polarizing concentrations
of ET or CyaA (Figure 6A and 6B).
To understand whether Th2 polarizing concentrations of ET
and CyaA could selectively affect downstream components of
TCR signaling specifically implicated in Th lineage committ-
ment, we focused on two molecules in the TCR signaling cascade,
the Rac/Cdc42 specific guanine nucleotide exchanger Vav1 and
the stress-activated kinase p38, which have been implicated in
human Th2 cell differentiation [28–32]. Furthermore, we
assessed the effect of the toxins on the serine/threonine kinase
Akt1, which has been associated to Th1 cell differentiation [9].
Strikingly, analysis of Akt1 activation using phosphospecific
antibodies which recognize two critical residues, T308 and
S473, showed that low, Th2 polarizing concentrations of ET or
CyaA were sufficient to potently impair TCR dependent Akt
phosphorylation (Figure 7A and data not shown). Conversely,
both basal and TCR dependent Vav1 phosphorylation on Y174,
which positively regulates Vav1 activity, was potentiated by low
concentrations of ET or CyaA (Figure 7B). A similar enhance-
ment was observed for p38 (Figure 7B), consistent with the
capacity of PKA to act as an agonist of this kinase [31,33]. The
phosphodiesterase inhibitor, IBMX, further potentiated the
agonistic activity of the toxins on p38 activation (data not shown),
further supporting the notion that the effects of the toxins are
mediated by cAMP. Hence ET and CyaA alter the Th1/Th2
balance at least in part by antagonizing the Akt1 dependent
pathway leading to Th1 cell differentiation and by potentiating
the Vav1 and p38 dependent pathway(s) leading to Th2 cell
differentiation. Of note, TCR dependent Vav1 and p38 activation
was not impaired, but actually enhanced, when cells were
pretreated with high concentrations of ET or CyaA (Figure 7B),
despite their potent inhibitory activity on initiation of TCR
signaling, suggesting that an Lck independent pathway triggered
by the TCR, which can be potentiated by cAMP, may contribute
to a significant extent to their activation.
Figure 4. CyaA and ET promote c-maf and GATA-3 expression in primed T cells. Enriched CD4+ T cells from 3 healthy donors were primed
with anti-CD3 mAb, as such or following pretreatment for 2 h with 0.28 nM CyaA or 0.11 nM ET. Cells primed in Th2- (IL-4) or Th1- (IL-12) inducing
conditions were included as controls. After 10 days cells were restimulated with anti-CD3 mAb for 24 h. The levels of mRNA encoding c-maf and
GATA-3 (A) and T-bet (B) were quantified by real-time RT–PCR. Transcript levels were normalized to the expression level of GAPDH. Syber green runs
were performed with cDNAs from the same reverse transcription reaction from 400 ng of total RNA. The DDCT method was applied as a comparative
method of quantification, using cells primed in neutral conditions (anti-CD3 mAb) as reference. The data are representative of 3 independent
experiments, each in duplicate. ***P#0.00001; **P#0.0001; *P#0.001. Error bars, SD.
doi:10.1371/journal.ppat.1000325.g004
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Discussion
The B. anthracis ET and B. pertussis CyaA adenylate cyclase
toxins act as potent suppressors of T cell activation and
proliferation in the 1029–1026 molar range of concentrations
[22–24]. In the absence of systemic intoxication, these high
concentrations are likely to be reached only locally through
accumulation of the toxins at the primary site of infection.
However, there are anatomical districts and localized infections
(e.g. cutaneous anthrax) where low amount of toxins may be
released and might modulate the host immune response. We
found that both ET and CyaA are potent promoters of naive
CD4+ T cell differentiation to Th2 effectors when used at
subnanomolar concentrations (0.1–0.3 nM). Interestingly, distinct
effects of high vs low concentrations of CyaA have also been
observed in neutrophils and other phagocytes, ranging from
cytolysis to apoptosis to impairment of effector functions [34],
suggesting the biological outcome of host cell exposure to the toxin
is likely to be dictated by its proximity to the bacterium. The
sensitivity of T cells to such low ET concentration can be
accounted for by the fact that human leukocytes express the high
affinity CMG2 receptor for protective antigen (PA), the receptor
binding subunit of ET [35]. Furthermore, although T cells lack
CD11b/CD18, the only known CyaA receptor, CyaA can
effectively insert into cell membranes or artificial lipid bilayers in
the absence of CD11b/CD18, albeit with a reduced efficacy [36].
The presence on T cells of a putative alternative CyaA receptor
cannot however be ruled out.
The immunosuppressant activity of high concentrations of ET
and CyaA is fully consistent with the known inhibitory effects of
cAMP on T cell activation. In physiological conditions cAMP
production by a TCR-coupled adenylate cyclase is part of a
negative feed-back loop which ensures extinction of TCR signaling
through PKA dependent activation of Csk, a kinase that inhibits
Lck by phosphorylating its C-terminal tyrosine residue [27]. This
feed-back loop does not become immediately operational because
cAMP production is counterbalanced by TCR dependent
recruitment of PDE-4 to lipid rafts, where also the activated
TCR localizes, thereby allowing the protein tyrosine kinase
cascade to start [37]. Once PDE-4 dissociates from lipid rafts,
the feed-back loop can terminate the signal. Since cAMP
production and PKA activation are TCR-dependent, cAMP
returns to basal levels after signal extinction. Alterations in this
finely regulated cAMP balance by adenylate cyclase agonists, such
as PGE2 receptors, result in impaired TCR signaling and T cell
activation [27]. The inhibitory activity of high concentrations of
ET and CyaA on Lck activation and CD3f phosphorylation
indicates that these toxins preventing firing of the TCR signaling
cascade by altering the cAMP balance through the massive and
sustained production of cAMP. In this context, it should be
underlined that TCR engagement results in a rapid elevation in
the levels of cAMP, which elicit a potent enhancement in PKA
activation, comparable to the one observed in cells exposed to high
toxin concentrations. Nevertheless, under these conditions the
TCR triggers a productive signaling cascade, as opposed to cells
pre-exposed to high concentrations of ET or CyaA, supporting the
Figure 5. Immunosuppressive concentrations of CyaA or ET prevent initiation of TCR signaling. (A) Top left, Immunoblot analysis, using a
phosphospecific antibody, of Lck phosphorylation on the inhibitory C-terminal tyrosine residue (Y505) in postnuclear supernatants from PBL
activated for 1 min by CD3 cross-linking in the presence or absence of either 45 nM CyaA or 110 nM ET (CyaA hi, ET hi). Top right, Immunoblot
analysis, using an anti-phosphotyrosine antibody, of CD3f specific immunoprecipitates from PBL treated as above. Bottom, Immunoblot analysis,
using phosphospecific antibodies, of ZAP-70 (left) and Erk1/2 (right) phosphorylation in postnuclear supernatants from PBL activated for 1 min (ZAP-
70) or 5 min (Erk1/2) by CD3 cross-linking in the presence or absence of 45 nM CyaA or 110 nM ET (CyaA hi, ET hi). (B) Quantification by laser
densitometry of the relative levels of Lck (phosphorylation in unstimulated cells taken as 100%), or CD3f, ZAP-70 and Erk1/2 phosphorylation
(phosphorylation in anti-CD3 stimulated cells taken as 100%, indicated as a dotted line) in PBL activated by CD3 cross-linking in the presence of
45 nM CyaA or 110 nM ET (CyaA hi, ET hi) (n$3). Where indicated, cells were activated in the presence of the adenylase cyclase deficient CyaA and ET
mutants (45 nM CyaA-E5, 110 nM EL1) for 2 h or 6 h, respectively (n=2). ***P#0.001; **P#0.01; *P#0.05. Error bars, SD.
doi:10.1371/journal.ppat.1000325.g005
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importance of the spatiotemporal regulation of cAMP in TCR
signaling. Low toxin concentrations on the other hand, do not
inhibit initiation of TCR signaling. The intracellular concentration
of cAMP measured under these conditions, which is very modest
compared to the burst of cAMP evoked by the TCR, may be
locally and transiently neutralized by PDE-4.
At variance with their inability to impair initiation of TCR
signaling, low concentrations of ET or CyaA were found to
selectively affect specific downstream nodes -Akt1, Vav1 and p38
activation- crucial to Th1/Th2 lineage committment. This activity
is likely to result from their PKA dependent modulation of
intracellular signaling mediators implicated in Th2 cell differen-
tiation downstream of signal initiation. Akt1 has been reported to
favour Th1 cell differentiation by providing the CD28 costimu-
latory signal required for expression of the Th1 cytokines IL-2 and
IFN-c [9]. Although our study was carried out on T cells
stimulated by TCR/CD3 cross-linking in the absence of CD28
costimulation, the results show that Akt1 is effectively phosphor-
ylated in response to TCR engagement and that this event is
potently inhibited by low concentrations of ET or CyaA. The
negative regulation of Akt by PKA [38,39] is likely to underlie this
inhibitory, TCR-distal effect of the two toxins, which would
moreover favour differentiation to the Th2 lineage by potentiating
the PDK1/PKA pathway coupling the TCR to IL-4 gene
transcription [9].
Under the same conditions, both toxins enhance TCR
dependent phosphorylation of the guanine nucleotide exchanger
Vav1 and activation of the stress kinase p38, which participate in
Th2 lineage commitment. A skewing of the Th1/Th2 balance to
Th1, as well as defects in Th2 dependent B cell responses, have
been indeed observed in Vav12/2 mice [28,40]. Furthermore,
p38 has been implicated in human Th2 cell differentiation, at least
in part through its capacity to promote activation of GATA-3 [29–
32]. The similar enhancement of TCR-dependent Vav and p38
activation in the presence of high toxin concentrations, which
block signal initiation, supports a local effect on a specific signaling
module independent of the TCR proximal, Lck-dependent
signaling cascade. While there is evidence for an agonistic role
of cAMP in p38 activation [31], the potential function of cAMP in
the modulation of Vav1 activity has not been directly addressed.
Figure 6. Low CyaA or ET concentrations do not affect initiation of TCR signaling. (A) Immunoblot analysis, using phosphospecific
antibodies, of CD3f, ZAP-70, or Erk1/2 phosphorylation in postnuclear supernatants of cells activated as above in the presence or absence of either
0.28 nM CyaA or 0.11 nM ET (CyaA lo, ET lo). Filters were stripped and re-probed with control antibodies. Representative experiments are shown
(n$3). The migration of molecular mass markers is indicated. (B) Quantification by laser densitometry of the relative levels of CD3f, ZAP-70, and Erk1/
2 phosphorylation (phosphorylation in anti-CD3 stimulated cells taken as 100%, indicated as a dotted line) in PBL activated by CD3 cross-linking in
the presence or absence of either 0.28 nM CyaA or 0.11 nM ET (CyaA lo, ET lo) (n$3). Error bars, SD.
doi:10.1371/journal.ppat.1000325.g006
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We have previously characterized a Fyn dependent, Lck
independent pathway linking the TCR to Vav1 phosphorylation
and p38 activation which could be potentiated by PGE2 [41].
Together with the evidence implicating Vav1 and p38 in Th2 cell
differentiation, the Th1 bias observed in Fyn2/2 mice [42,43]
may suggest a potential involvement of this cAMP sensitive
pathway in the Th2 promoting activity of ET and CyaA.
It is noteworthy that the effects of ET and CyaA are almost
undistinguishable, notwithstanding their differences in stucture,
mode of cell entry and intracellular localization. ET is an A–B type
toxin, consisting of a cell binding component, PA, which targets
cells via the receptors TEM8 or CMG2, and a toxin component,
EF. ET enters the cell by receptor mediated internalization and is
transported to the endosomes, wherefrom it is released into the
Figure 7. Low CyaA or ET concentrations impair TCR–dependent Akt1 phosphorylation while enhancing Vav1 and p38
phosphorylation. (A) Immunoblot analysis, using a phosphospecific antibody, of Akt1 activation in postnuclear supernatants from PBL activated for
5 min by CD3 cross-linking in the presence or absence of 45 nM CyaA or 110 nM ET (CyaA hi, ET hi) or alternatively in the presence or absence of
0.28 nM CyaA or 0.11 nM ET (CyaA lo, ET lo). A representative experiment is shown (n= 3). (B) Immunoblot analysis, using phosphospecific antibodies,
of Vav1 (top) or p38 (bottom) activation in postnuclear supernatants from PBL activated for 1 min (Vav) or 5 min (p38) by CD3 cross-linking in the
presence or absence of 45 nM CyaA or 110 nM ET (CyaA hi, ET hi) or alternatively in the presence or absence of 0.28 nM CyaA or 0.11 nM ET (CyaA lo,
ET lo). Filters were stripped and re-probed with control antibodies. Representative experiments are shown (n$4). The migration of molecular mass
markers is indicated. The graphs on the right of the immunoblots show the quantification by laser densitometry of the relative levels of Akt1, Vav1,
and p38 phosphorylation (phosphorylation in anti-CD3 stimulated cells taken as 100%) in PBL activated by CD3 cross-linking in the presence or
absence of 45 nM CyaA or 110 nM ET (CyaA hi, ET hi) or alternatively in the presence or absence of 0.28 nM CyaA or 0.11 nM ET (CyaA lo, ET lo).
***P#0.001**P#0.01; *P#0.05. Error bars, SD.
doi:10.1371/journal.ppat.1000325.g007
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cytosol [11]. CyaA is a single polypeptide which binds to target
cells both directly and through a membrane receptor, which in
macrophages and other APC is the integrin CD11b/CD18 [44].
Following binding, the adenylate cyclase N-terminal domain is
translocated accross the plasma membrane of target cells [12].
Hence EF and CyaA produce cAMP not only with different
kinetics, which is delayed for ET probably due to the multistep
mechanism of delivery into host cells, but also at different
subcellular locations, in the cytosol with a prevalent perinuclear
localization, and close to the plasma membrane, respectively [45–
47]. The role of AKAPs in segregation of PKA pools at specific
subcellular localizations and dynamic recruitment of phosphodi-
esterases underscores the importance of the spatiotemporal control
of cAMP signaling [48]. By focalizing cAMP production at distinct
sites within the cell, EF and CyaA could differentially affect early
and late events in TCR signaling. Our findings indicate that the
critical targets of the cAMP dependent Th2 polarizing activities of
ET and CyaA can be activated independently of the subcellular
site of cAMP production. It is likely that the sustained cAMP
production overrides the negative local feedback mechanisms,
resulting in loss of compartmentalization of cAMP dependent
signaling. It should be however underlined that low ET
concentrations are almost as effective as high concentrations in
triggering PKA activation, suggesting that ET may modulate other
functions, such as CREB mediated gene expression [45,47],
through activation of specific PKA pools.
Both ET and CyaA have been reported to potentiate antibody
responses and development of antigen specific Th2 cells in mice
when coadministered with antigen [13–17]. This adjuvant activity
had been related to their capacity to modulate cytokine production
by dendritic cells and macrophages in vitro, resulting in reduction
in IL-12 and enhancement in IL-10 and IL-4 expression [13–
16,18,19]. Our finding that ET and CyaA directly affect the Th1/
Th2 balance by favouring Th2 cell development suggests that their
adjuvanticity is also due to their effects on CD4+ T cells. This
activity appears mediated by cAMP, as it cannot be reproduced by
the respective enzymatically deficient mutants. The Th2 polariz-
ing effects of these toxins resulting from their modulation of
cytokine expression by APC have also been related to their cAMP
elevating activity [15,18,19,49]. Consistent with these findings,
both non-hydrolysable cAMP analogues and PGE2 have been
reported to favour Th2 cell development both by directly affecting
CD4+ T cell differentiation [4,6,8] and by shaping the pattern of
cytokine production by APC [19–21]. The Th2 driving activity of
ET may be very relevant to cutaneous anthrax, where there is a
limited toxin production and where resolution of infection has
been causally linked to the development of an antibody response
against the toxin [50,51].
As opposed to the clear-cut role of cAMP in both the direct and
the APC dependent Th2 driving activity of ET or CyaA in vitro, the
role of cAMP in the adjuvanticity of the toxins in vivo is more
controvertial. While the adjuvant activity of adenylate cyclase
deficient ET mutants has as yet not been tested in vivo, there are
discrepancies as to the adjuvanticity of catalytically inactive CyaA
mutants, which have been proposed to result from a number of
factors, including the genetic background of the mouse strain, the
route of antigen delivery, the dose of CyaA mutant and the
vaccination schedule [14,15,52,53]. Genetically detoxified mutants
of other cAMP elevating toxins such as CT or LT-I, or their
individual B (binding) subunits, have been demonstrated to retain
adjuvant activity [10], indicating that both cAMP production and
toxin binding to specific receptors contribute to their adjuvanticity.
This possibility has been ruled out for ET, as PA does not harbour
any activity either on APC or T cells in vitro nor acts as an adjuvant
in vivo [16]. On the other hand, at variance with other reports
[15,53], an enzymatically deficient CyaA mutant, highly purified
to rule out a contamination by LPS, has been reported to display
adjuvant properties comparable or even superior to wild-type
CyaA [14,52]. A potential implication of CD11b/CD18 in the
adjuvanticity of CyaA appears unlikely, as this integrin suppresses
cytokine production by dendritic cells [54,55], and moreover does
not account either for the immunodeviating activity of CyaA on
APC in vitro, which is cAMP dependent [15,18,19], or for the
conflicting results obtained by different groups in vivo
[14,15,52,53]. An integrated and detailed analysis of the structural
and functional interaction of adenylate cyclase toxins with the
different cellular components which together orchestrate the
immune response is expected not only to clarify their mechanism
of adjuvanticity but also to lead to the development of more
specific and effective adjuvants.
Materials and Methods
Cells, antibodies, reagents, and toxins
Peripheral blood mononuclear cells were purified from buffy
coats from anonymous healthy donors (collectively ,30, available
from authorised blood banks) by density gradient centrifugation on
Ficoll-Paque (Amersham Biosciences, Buckinghamshire, UK), using
a Beckman GS-6R tabletop centrifuge (Beckman Coulter SpA,
Milan, Italy). Cells were washed 26 in phosphate buffered saline
(PBS), resuspended in RPMI 1640 (Invitrogen Ltd, Paisley, UK)
(buffered with sodium bicarbonate to pH 7.2) supplemented with
7.5% fetal calf serum (FCS) (Hyclone, Thermofischer Scientific Inc,
SouthLogan, UT), plated in plastic flasks (Sarstedt AG, Numbrecht,
Germany) and incubated overnight at 37uC in a humidified
atmosphere with 5% CO2. Non-adherent cells, which consisted
principally of peripheral blood lymphocytes (PBL) and of which
.90% were T cells (CD3+), were centrifuged at 8006g for 5 min at
room temperature in Beckman GS-6R tabletop centrifuge and
resuspended in fresh RPMI 1640 supplemented with 7.5% FCS.
For cAMP measurement, T cells were purified from peripheral
blood mononuclear cell suspensions using the StemSep Human T
cell enrichment kit (Voden Medical Instruments SpA, Milan,
Italy).
Phosphospecific antibodies recognizing the phosphorylated
active forms of CD3f, ZAP-70 (Y493), Vav1 (Y160), Akt1
(T308/S473), Erk1/2 (T202/Y204), p38 (T180/Y182) and CREB
(S133), as well as an antibody recognizing phosphorylated Y505
on Lck, were from Cell Signaling Technology (Beverly, MA),
Santa Cruz Biotechnology (Santa Cruz, CA) and Biosource
Europe SA (Nivelles, Belgium). An antibody against the phos-
phorylated PKA consensus phosphorylation site, R-X-X-pT-X-
X/R-R-X-pS-X-X, was purchased from Cell Signaling Technol-
ogy. Anti-CD3f, -Lck, ZAP-70, -Vav, -Erk2, -p38, -CREB and
anti-actin antibodies were from Santa Cruz Biotechnology,
Upstate Biotechnology (Dundee, UK) and Cell Signaling Tech-
nology. A mAb suitable for immunoprecipitation of tyrosine
phosphorylated CD3f was kindly provided by M. Banyiash.
Fluorochrome-labeled anti-CD3 mAb were obtained from Becton
Dickinson Biosciences (Milan, Italy). Unlabeled secondary anti-
bodies were purchased from Cappel (ICN Pharmaceuticals Inc,
CA) and peroxidase labeled antibodies from Amersham Biosci-
ences. IgG antibodies from OKT3 (anti-CD3; American Type
Culture Collection, Manassas, VA) hybridoma supernatants were
purified on Mabtrap (Amersham Biosciences, Inc) and titrated by
flow cytometry.
CyaA and the enzymatically inactive variant CyaA-E5 (resulting
from a Leu-Gln dipeptide insertion between D188 and I189 in the
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catalytic core of the enzyme) were expressed in E. coli and purified
to near homogeneity by previously established procedures
modified as described [56] in order to eliminate most of the
contaminating endotoxin. The specific activity of CyaA, measured
as described in Ladant et al. [26] was higher than 500 mmol
cAMP/min.mg whereas CyaA-E5 had no detectable enzymatic
activity. In both preparations the endotoxin content, determined
using a LAL assay (QCL-1000 kit from Lonza), was below
0.5 EU/mg protein. PA, LF and EL1 were expressed in E. coli and
purified as described [25,45,57]. H89, KT5720, IBMX and 8-
CPT were purchased from Sigma-Aldrich (Milan, Italy) and
Calbiochem (Merck Biosciences GmbH, Schwalboch, Germany).
Cell activations and lysis, immunoblots
For immunoblot analyses cells were plated at 56106 cells/ml in
plastic flasks in RPMI 1640 supplemented with 7.5% FCS and
2 mM CaCl2 (required for CyaA entry into the cells), added with
CyaA/CyaA-E5, and incubated at 37uC in a humidified
atmosphere with 5% CO2 for 2 h before activation. Alternatively,
cells were plated as above, added with ET (ratio PA:EF 1.6), and
incubated at 37uC for 6 h before activation. Activations by TCR/
CD3 cross-linking were performed by incubating PBL with
saturating concentrations of anti-CD3 mAb (as assessed by flow
cytometry) and 50 mg ml21 secondary antibodies (goat anti-mouse
immunoglobulin Ig) in RPMI 1640 for 1–5 min at 37uC as
previously described [58]. None of the above mentioned
treatments affected cell viability, as assessed by Trypan blue
exclusion (data not shown). When required, cells were pretreated
with the PKA inhibitors, H89 (20 mM) and KT5720 (56 nM), or
with the PDE inhibitor, IBMX (0.5 mM), for 1 h before addition
of ET or CyaA. Alternatively, cells were treated for 30 min with 8-
CPT (100 mM).
Cells were recovered by centrifugation at 16,0006g for 30 sec at
4uC in an Eppendorf 5415R microcentrifuge (Eppendorf srl,
Milan, Italy), washed 26 in PBS and lysed in 1% (v/v) Triton X-
100 in 20 mM Tris-HCl pH 8, 150 mM NaCl (in the presence of
0.2 mg/ml Na orthovanadate, 1 mg/ml pepstatin, leupeptin, and
aprotinin, and 10 mM phenyl methyl sulfonyl fluoride). To
normalize for variations in protein content among samples, equal
amounts of proteins from each sample (measured using a kit from
Pierce, Rockford, IL) were resolved by 12% SDS-PAGE and
transferred to 0.45-mm nitrocellulose filters Whatman GmbH,
Dassel, Germany). Prestained molecular mass markers (Invitrogen)
were included in each gel.
Immunoblots were carried out using primary antibodies and
peroxidase-labeled secondary antibodies according to the manu-
facturers’ instructions and a chemiluminescence detection kit
(Pierce). Blots were scanned using a laser densitometer (Duoscan
T2500 Agfa, Milan, Italy) and quantified using the ImageQuant
5.0 software (Molecular Dynamics, Sunnyvale, CA). Data were
normalized to loading controls.
T cell proliferation assays, cytokine, and cAMP
measurements
For proliferation assays, cells (26105/sample) were plated in 96-
well plates in RPMI 1640 supplemented with 7.5% FCS (and
2 mM CaCl2 for CyaA treatments and respective controls), added
with CyaA/CyaA-E5 (0.07–45 nM) or ET/EL1 (0.01 pM–
1.1 nM), and incubated at 37uC in a humidified atmosphere with
5% CO2 for 2 h (CyaA) or 6 h (ET) before activation. Cells were
activated by CD3 cross-linking on secondary antibody-coated
plates as described [58] and processed 16–48 h after activation.
[3H]-thymidine (1 mCi) was added to each microtiter well (96-well
plates) for the last 18 h of culture. After harvesting the cells with an
automatic harvester (Micromate 196, Canberra Packard, Mer-
iden, CT), proliferation was determined by measuring the
[3H]thymidine (Amersham, Buckinghamshire, UK) incorporation
in a b-counter (Matrix 9600, Canberra Packard, Meriden, CT).
To measure Th cell differentiation, enriched human CD4+ T
cells were activated by immobilized anti-CD3 mAb (purified from
OKT3 hybridoma supernatants on Mabtrap, Amersham Biosci-
ences Europe) as described [59], in the absence or presence of
recombinant hIL-12 (2 ng/ml, Sigma-Aldrich Milan, Italy) to
promote Th1 differentiation, or recombinant hIL-4 (10 ng/ml,
Sigma-Aldrich Milan, Italy) to promote Th2 differentiation.
Recombinant hIL-2 (kindly provided by Eurocetus Milan, Italy)
was added to the cultures on day 4 and 7. After 10 days, cells
(16106) were washed, stimulated for 24 h or 48 h using anti-CD3
mAb and the levels of IL-4, IL-13, IFNc and TNF-a were
measured by ELISPOT as described [59].
Intracellular cAMP was quantitated by enzyme-linked immu-
noassay kit (Biotrak EIA, Amersham Biosciences) according to the
manufacturers’ instructions. For these experiments, cells (16106
plated in 96-well plates in 200 ml RPMI 1640/7.5% FCS) were
treated with CyaA/CyaA-E5 or ET/EL1 as described above for
30 min to 24 h in a humidified atmosphere with 5% CO2. At the
end of the treatment, cells were washed 26in PBS and lysed in the
lysis reagent included in the kit.
RNA purification and real-time quantitative RT–PCR
Total RNA was extracted from Th cells, polarized as described
above, using Tri Reagent (Ambion, Austin, TX). Reverse transcrip-
tion-polymerase chain reaction (RT-PCR) was carried out on
400 ng total RNA using ImProm-IITM reverse transcriptase and and
oligo-dT (Promega Italia srl, Milan, Italy) as first strand primer.
Real-time quantitative PCR was performed using SYBR Green
I SensiMixTM dT Kit (Quantace, Watford, UK) according to the
manufacturer’s instructions, in an Opticon 2 Continuous Fluores-
cence Detection System (MJ Research, Bio-Rad Laboratories,
Waltham, MA). All samples were run in duplicate on 96-well
optical PCR plates (Roche Diagnostics, Milan, Italy). The specific
primers used to amplify cDNA fragments corresponding to c-maf,
GATA-3, T-bet and GAPDH were: 59-TGGAGTCGGAGAA-
GAACCAG-39 (sense), 59-GCTTCCAAAATGTGGCGTAT-39
(antisense) for c-Maf; 59-GAAGGAAGGCATCCAGACCAG-39
(sense), 59-ACCCATGGCGGTGACCATGC-39 (antisense) for
GATA-3; 59-TAATAACCCCTTTGCCAAAGG-39 (sense); and
59-TCCCCCAAGGAATTGACAGT-39 (anti-sense) for T-bet and
59-TGCACCACCAACTGCTTAGC-39 (sense) and 59-
GGCATGGACTGTGGTCATGAG-39 (anti-sense) for GAPDH.
After an initial denaturation for 10 min at 95uC, denaturation at
the subsequent 40 cycles was performed for 15 s at 95uC, followed
by 15 s primer annealing at 60uC and a final extension at 72uC for
30 s. The DDCT method [60] was applied as a comparative
quantification method. The specificity of the amplified fragment
was demonstrated by the melting curve, where a single peak was
observed for each sample amplified with c-maf, GATA-3, T-bet
and GAPDH primers. c-maf, GATA-3 and T-bet mRNA levels
were normalized to GAPDH, used as a housekeeping gene.
Statistical analyses
Mean values, standard deviation values and Student’s t test
(unpaired) were calculated using the Microsoft Excel application.
A level of P,0.05 was considered statistically significant.
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